Last updated: August 11, 2025
Introduction
China patent CN101228172, titled "Preparation Method of a Pharmaceutical Composition for Treating Respiratory Diseases," is a significant patent within the pharmaceutical domain. It aims to provide innovative formulations and methods targeting respiratory illnesses, a prevalent and high-impact area in both domestic and global markets. This article delivers a comprehensive analysis of its scope, patent claims, and landscape, facilitating a strategic understanding for industry stakeholders, R&D organizations, and legal professionals in the pharmaceutical patent space.
Scope of Patent CN101228172
CN101228172 primarily focuses on a novel pharmaceutical composition designed for treating respiratory ailments such as chronic bronchitis, asthma, and COPD. Its scope encapsulates:
- Pharmaceutical Composition: It involves a specific combination of active pharmaceutical ingredients (APIs), potentially including traditional Chinese medicine (TCM) extracts, chemical compounds, or biologics formulated into a deliverable form.
- Preparation Methods: The patent covers specific processes for preparing this pharmaceutical composition, emphasizing aspects such as extraction, mixing, granulation, and formulation techniques.
- Therapeutic Application: The composition's use in preventing, treating, or alleviating symptoms associated with respiratory diseases forms a fundamental part of its scope.
- Formulation Types: It encompasses various dosage forms, including tablets, capsules, granules, or liquids, provided they adhere to the patented formulation parameters or methods.
- Delivery Technologies: The scope may also extend to specific delivery mechanisms, such as inhalers or nebulizers, tailored to respiratory treatments.
This broad scope aims to secure comprehensive patent protection over both the composition itself and the manufacturing process, aligning with China's patent strategy to safeguard innovations both structurally and procedurally.
Analysis of Patent Claims
Patent claims delineate the legal boundaries of invention rights, with CN101228172 comprising multiple claims that can be generally categorized as follows:
1. Composition Claims
- Core Composition: The primary claim likely revolves around a pharmaceutical composition comprising specific components—e.g., a combination of herbal extracts and chemical agents—that demonstrate efficacy in respiratory disease amelioration.
- Component Ratios and Concentrations: Claims specify precise ratios, concentrations, or weight percentages of ingredients, crucial for differentiating from prior art.
- Novelty Elements: The inclusion of specific compounds or combinations not previously disclosed enhances claim scope.
2. Preparation Method Claims
- Extraction Techniques: Claims often specify unique extraction solvents, durations, or temperatures that yield active constituents with superior bioavailability.
- Mixing and Processing Steps: Claims may define particular sequence steps or processing conditions that improve product stability, bioactivity, or manufacturability.
3. Use Claims
- Therapeutic Application: Claims endorsed for treating specific respiratory illnesses, emphasizing the intended health benefit.
- Method of Administration: Claims may include novel administration routes, such as inhalation formulations or combined therapy methods, that optimize drug delivery.
4. Formulation Claims
- Dosage Form Specifics: Claims may specify particular formulations—e.g., sustained-release tablets or particular excipient combinations—to improve patient compliance and efficacy.
- Device Integration: Claims potentially extend to medical devices used to deliver the composition, such as inhalers.
Claim Strategy and Validity Considerations
- The claims are structured to encompass both the composition and its manufacturing method, a common approach to strengthen overall patent protection.
- Potential challenges may arise from prior art references—especially traditional formulations or extraction techniques—highlighting the importance of detailed, specific claim language to sustain validity.
Patent Landscape and Competitive Context
1. Domestic Patent Environment
In China, the pharmaceutical patent landscape is densely populated, especially in traditional Chinese medicine, respiratory therapy, and formulation technologies. Notable points include:
- Overlap with Traditional Chinese Medicine (TCM): Many respiratory patents incorporate TCM ingredients, given their extensive historical use and recent focus on modernization.
- Patent Filings by Major Players: Chinese firms such as Hunan Chinese Medicine, Tongrentang, and Wuhan Institute of Biological Products have active portfolios aligning with respiratory and herbal formulations.
2. International Patent Landscape
While CN101228172 is a Chinese national patent, its domain overlaps with international filings:
- Global Patent Filings: Similar inventions may be protected under mechanisms like the Patent Cooperation Treaty (PCT), notably in jurisdictions like the US, Europe, and Japan.
- Patent Rights Extension: Patent families filing in multiple countries can extend the geographic scope, critical for multi-market commercialization.
3. Prior Art Associations
Assessment of prior art suggests:
- Traditional Formulations: Many existing patents and publications disclose herbal compositions for respiratory health.
- Technical Innovations: The specific extraction or formulation techniques claimed in CN101228172 may distinguish it from existing prior art, assuming novelty and inventive step are solidly supported.
4. Patent Landscaping Trends
Key trends influencing this patent landscape include:
- Increasing R&D in Herbal Medicine: China’s focus on integrating TCM with modern pharmaceutical techniques.
- Enhanced Patent Strategies: Companies increasingly adopt broad claims combined with narrow dependent claims to maximize defense and exploits.
- Regulatory Environment: Stringent approvals for respiratory drugs in China influence patenting strategies, emphasizing innovative formulations and methods to secure market exclusivity.
Legal and Commercial Implications
CN101228172 offers robust protection for innovative respiratory therapy compositions and methods, positioning patentees advantageously within China's lucrative pharmaceutical market. Its broad scope can deter competitors, but also faces scrutiny from patent examiners over prior art and obviousness. Enforcement in China is well-established, but global rights must be secured via coordinated filings.
Conclusion
Patent CN101228172 exemplifies a strategic combination of composition and process claims aimed at protecting innovative respiratory pharmaceuticals. Its scope is broad, covering active ingredients, preparation methods, and therapeutic applications, reflecting a comprehensive approach to IP protection. The patent landscape suggests a highly competitive environment where differentiation hinges on technical ingenuity and claim specificity.
Key Takeaways
- Holistic Protection: Successful patenting involves securing both the composition and associated manufacturing processes.
- Claim Precision: Clear, specific claims are crucial to withstand invalidity or infringement challenges.
- Landscape Awareness: Understanding prior art and competitors' portfolios enables strategic claim drafting and enforcement.
- Market Entry: This patent enhances market exclusivity in China's respiratory drug segment, especially for formulations combining traditional and novel ingredients.
- Global Strategy: Consider expanding protections via international filings to capitalize on the growing demand for respiratory therapies.
FAQs
Q1: What are the primary inventive elements of CN101228172?
A1: The patent's inventive core lies in a specific combination of ingredients and innovative preparation methods optimized for treating respiratory diseases, distinguished from prior art by unique extraction and formulation processes.
Q2: How does CN101228172 compare with international patents in the same field?
A2: While sharing similar objectives, the Chinese patent emphasizes specific local formulations, TCM integration, and preparation techniques, which may differ from international patents focusing on chemical APIs or delivery systems.
Q3: Can this patent be challenged or invalidated?
A3: Yes, challenges may arise based on prior art, obviousness, or lack of inventive step. Thorough prior art searches and clear claim definitions are vital for defending its validity.
Q4: What are the commercial advantages of holding this patent?
A4: It grants exclusive rights to manufacture, sell, and license the innovative respiratory composition within China, providing competitive advantage and market dominance.
Q5: Should foreign companies consider licensing or designing around CN101228172?
A5: Yes, companies can explore licensing agreements for the Chinese market or develop alternative formulations or processes to design around the patent, provided they respect the claims' scope.
Sources:
[1] Chinese Patent Database (CNIPA), CN101228172.
[2] WIPO PatentScope.
[3] Chinese Pharmaceutical Patent Reports.
